Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Athanassios Argiris

Hematology & Oncology San Antonio, TX Medical Doctor

NPI 1174608509 CMS profile 8229

7979 Wurzbach Rd, Urschell Tower, 6Th Floor, San Antonio, TX 78229

Open in the dashboard

General payments

$49,676

24 records reported · program years 2019–2024

Research payments

$28,908

Paid to them · 8 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$35,066 paid to institutions, not to them · program year 2022

Through program year 2024, Athanassios Argiris of San Antonio, TX is reported in the CMS Open Payments database as having received $49,676 across 24 general payments and $28,908 in research payments paid to them. Separately, studies naming them as principal investigator received $35,066 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $3,800 1
2023 General $5,700 2
2023 Research $12,935 4
2022 General $25,654 11
2022 Research $12,174 3
2021 General $8,220 2
2020 General $9,343 6
2019 General $759 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Athanassios Argiris
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Athanassios Argiris were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Athanassios Argiris Hematology & Oncology median Middle half National median
2019 $759 $529 $121–$2,516 $163
2020 $9,343 $339 $82–$2,213 $114
2021 $8,220 $263 $49–$1,965 $132
2022 $25,654 $416 $103–$2,395 $149
2023 $5,700 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca UK Limited $30,140 7 payments
  2. Merck Sharp & Dohme Corporation $6,559 6 payments
  3. Seattle Genetics, Inc. $5,918 5 payments
  4. EMD Serono Research & Development Institute, Inc. $5,700 2 payments
  5. E.R. Squibb & Sons, L.L.C. $759 3 payments
  6. Celgene Corporation $600 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $41,478 11 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,100 1 payment
  3. Travel and Lodging $1,924 8 payments
  4. Food and Beverage $175 4 payments
Research payments came from Research payments · program years 2019–2024
  1. Merck Healthcare KGaA $12,935 4 payments
  2. EMD Serono, Inc. $12,174 3 payments
  3. EMD Serono Research & Development Institute, Inc. $3,800 1 payment

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record